Arq Bras Endocrinol Metab 2012;56(8):570-573

Oncogenic osteomalacia: loss of hypophosphatemia might be the key to avoid misdiagnosis

Claudia V. , Sandro J. , Renata A. M. , Vânia S. , Milla C. , Andre C. , Susan C. , Flávia H. , José V. , Glaucia M. F. S. , Peter , Célia R.

DOI: 10.1590/S0004-27302012000800018

Diagnosing oncogenic osteomalacia is still a challenge. The disorder is characterized by osteomalacia caused by renal phosphate wasting and low serum concentration of 1,25-dihydroxyvitamin D3 occurring in the presence of a tumor that produces high levels of fibroblast growth factor 23. However, it is possible that the disease is much more misdiagnosed than rare. We present the case of a 42-year-old man with a long-term history of undiagnosed progressive muscle weakness. His laboratory results mainly showed low serum phosphate. Surgical removal of a nasal hemangiopericytoma that had been diagnosed five years earlier, brought him to a symptom-free condition. Even though knowing the underlying etiology would explain his osteomalacia, the patient sought medical help from countless physicians for five consecutive years, and only after adequate treatment a rewarding outcome was achieved. Arq Bras Endocrinol Metab. 2012;56(8):570-3

Oncogenic osteomalacia: loss of hypophosphatemia might be the key to avoid misdiagnosis

Comments (0)